Evidence map›Paper›PMID 27417511›Full record

ArticleJournal of clinical pharmacology2017

Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.

Laura A Wang, Daniel Gonzalez, J Steven Leeder, Rachel F Tyndale, Robin E Pearce, Daniel K Benjamin, Gregory L Kearns, Michael Cohen-Wolkowiez, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Metronidazole exposure-response and safety in infants.Antimicrobial agents and chemotherapy · 2025
    Trial
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Laura A WangDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Daniel GonzalezDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
J Steven LeederDepartment of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Rachel F TyndaleCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Departments of Pharmacology & Toxicology and Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Robin E PearceDepartment of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Daniel K BenjaminDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Gregory L KearnsArkansas Children's Hospital Research Institute and the Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Michael Cohen-WolkowiezDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
Duke University · USChildren's Mercy Hospital · USClinical Research Institute · USUniversity of Arkansas for Medical Sciences · USUniversity of Missouri–Kansas City · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

Duke CTSA (Composite)UL1TR001117 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, LI, JENNIFER S · 2013 to 2017
$41.3M
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in ChildrenR01HD076676 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2014 to 2017
$2.6M
Mentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5M
Use of Physiologically-Based PK/PD Models to Streamline Drug ApprovalsK23HD083465 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GONZALEZ, DANIEL · 2015 to 2019
$727k
Clinical Practice Data to Aid Narrow Therapeutic Index Drug ClassificationU01FD004858 · FDA · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2013 to 2014
$497k
Cognitive and Behavioral Effects of Sleep Restriction in Adolescents with ADHDR03MH109787 · NIMH · CINCINNATI CHILDRENS HOSP MED CTR · PI BECKER, STEPHEN P · 2016 to 2017
$156k
FDA HHS U01 FD004858NCATS NIH HHS UL1 TR001117NIAID NIH HHS HHSN272201300017CNIAID NIH HHS HHSN272201300017INIAID NIH HHS HHSN272201500006CNICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS K23 HD083465NICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD076676NIMH NIH HHS R03 MH109787
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic VariationAnti-Infective AgentsCohort StudiesCytochrome P-450 Enzyme SystemFemaleHumansInfant, NewbornMaleMetronidazoleAnti-Infective AgentsCytochrome P-450 Enzyme SystemMetronidazolemetabolismmetronidazoleneonatespharmacokinetics

Identifiers

PMID27417511
PMCPMC5233579
OpenAlexW2474151176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.